One of these CAR T cells, bb2121, is currently under investigation in a phase I clinical trial on patients with refractory MM who have ≥ 50% BCMA expression on their plasma cells (NCT02658929). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.